Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Axsome Therapeutics (AXSM) Financials

Axsome Therapeutics logo
$116.38 -2.13 (-1.79%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Axsome Therapeutics

Annual Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 -27 -29 -31 -68 -103 -130 -187 -239 -287
Consolidated Net Income / (Loss)		 -12 -27 -29 -31 -68 -103 -130 -187 -239 -287
Net Income / (Loss) Continuing Operations		 -12 -27 -29 -31 -68 -103 -130 -187 -239 -287
Total Pre-Tax Income 		-12 -28 -29 -31 -68 -103 -130 -187 -238 -287
Total Operating Income		 -9.20 -28 -27 -33 -67 -99 -125 -180 -232 -281
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 45 245 352
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50 271 386
Operating Revenue		 - - - - - 0.00 0.00 50 271 386
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.20 26 33
Operating Cost of Revenue		 - - - - - 0.00 0.00 5.20 26 33
Total Operating Expenses		 9.20 28 27 33 67 99 125 225 476 633
Selling, General & Admin Expense		 2.42 6.34 7.21 9.35 14 29 67 159 323 411
Research & Development Expense		 6.78 21 20 23 54 70 58 58 98 187
Amortization Expense		 - - - - - 0.00 0.00 4.14 6.38 6.39
Other Operating Expenses / (Income)		 - - - - - 0.00 0.00 3.30 49 28
Total Other Income / (Expense), net		 -3.29 -0.13 -1.99 1.66 -1.24 -3.81 -5.70 -7.34 -6.45 -6.57
Interest & Investment Income		 -0.74 -0.13 -1.34 -1.13 -1.24 -2.57 -5.70 -7.34 -6.45 -6.57
Income Tax Expense		 - - - -0.22 - -0.05 0.00 0.00 0.96 0.09
Other Gains / (Losses), net		 0.00 0.47 0.21 - 0.14 - 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($1.02) ($1.42) ($1.27) ($1.15) ($2.01) ($2.77) ($3.47) ($4.60) ($5.27) ($5.99)
Weighted Average Basic Shares Outstanding		 11.95M 19.15M 22.76M 26.88M 34.02M 37.21M 37.62M 40.66M 45.43M 47.91M
Diluted Earnings per Share		 ($1.02) ($1.42) ($1.27) ($1.15) ($2.01) ($2.77) ($3.47) ($4.60) ($5.27) ($5.99)
Weighted Average Diluted Shares Outstanding		 11.95M 19.15M 22.76M 26.88M 34.02M 37.21M 37.62M 40.66M 45.43M 47.91M
Weighted Average Basic & Diluted Shares Outstanding		 11.95M 19.15M 22.76M 26.88M 34.02M 37.21M 37.62M 43.52M 47.37M 48.77M

Quarterly Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -45 -61 -11 -67 -62 -99 -68 -79 -65 -75 -59
Consolidated Net Income / (Loss)		 -45 -61 -11 -67 -62 -99 -68 -79 -65 -75 -59
Net Income / (Loss) Continuing Operations		 -45 -61 -11 -67 -62 -99 -68 -79 -65 -75 -59
Total Pre-Tax Income 		-45 -61 -8.64 -68 -63 -99 -68 -79 -65 -75 -59
Total Operating Income		 -42 -60 -6.37 -65 -62 -98 -67 -78 -63 -73 -57
Total Gross Profit		 15 22 87 42 51 64 69 79 96 108 112
Total Revenue		 17 24 95 47 58 72 75 87 105 119 121
Operating Revenue		 17 24 95 47 58 72 75 87 105 119 121
Total Cost of Revenue		 1.92 2.29 7.56 4.60 6.53 7.38 6.30 8.06 8.44 11 9.79
Operating Cost of Revenue		 1.92 2.29 7.56 4.60 6.53 7.38 6.30 8.06 8.44 11 9.79
Total Operating Expenses		 57 82 93 107 113 162 136 157 159 181 169
Selling, General & Admin Expense		 41 61 74 79 83 87 99 104 96 113 121
Research & Development Expense		 15 15 18 21 29 31 37 50 45 55 45
Amortization Expense		 1.61 1.61 1.57 1.59 1.61 1.61 1.59 1.59 1.61 1.61 1.57
Other Operating Expenses / (Income)		 -0.04 4.20 -0.16 6.05 -0.18 43 -1.41 2.16 16 11 1.51
Total Other Income / (Expense), net		 -2.41 -1.32 -2.26 -2.73 -0.76 -0.70 -1.08 -1.30 -1.98 -2.21 -2.43
Interest & Investment Income		 -2.41 -1.32 -2.26 -2.73 -0.76 -0.70 -1.08 -1.30 -1.98 -2.21 -2.43
Income Tax Expense		 0.00 - 2.58 -0.62 -0.68 -0.33 0.00 0.00 0.00 0.09 0.00
Basic Earnings per Share		 ($1.07) ($1.44) ($0.26) ($1.54) ($1.32) ($2.15) ($1.44) ($1.67) ($1.34) ($1.54) ($1.22)
Weighted Average Basic Shares Outstanding		 41.70M 40.66M 43.52M 43.67M 47.12M 45.43M 47.39M 47.57M 48.14M 47.91M 48.87M
Diluted Earnings per Share		 ($1.07) ($1.44) ($0.26) ($1.54) ($1.32) ($2.15) ($1.44) ($1.67) ($1.34) ($1.54) ($1.22)
Weighted Average Diluted Shares Outstanding		 41.70M 40.66M 43.52M 43.67M 47.12M 45.43M 47.39M 47.57M 48.14M 47.91M 48.87M
Weighted Average Basic & Diluted Shares Outstanding		 43.43M 43.52M 43.57M 47.19M 47.32M 47.37M 47.50M 48.00M 48.46M 48.77M 49.24M

Annual Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 45 -11 -2.60 -20 206 -36 -97 114 185 -71
Net Cash From Operating Activities		 -7.44 -21 -26 -30 -46 -78 -108 -117 -145 -128
Net Cash From Continuing Operating Activities		 -7.44 -21 -26 -30 -46 -78 -108 -117 -145 -128
Net Income / (Loss) Continuing Operations		 -12 -27 -29 -31 -68 -103 -130 -187 -239 -287
Consolidated Net Income / (Loss)		 -12 -27 -29 -31 -68 -103 -130 -187 -239 -287
Depreciation Expense		 0.00 0.02 0.04 0.05 0.04 0.02 0.08 0.26 0.46 0.53
Amortization Expense		 0.05 0.07 0.47 0.38 0.65 0.84 1.08 5.62 8.95 10
Non-Cash Adjustments To Reconcile Net Income		 3.78 2.03 2.72 -1.04 6.12 23 21 41 113 114
Changes in Operating Assets and Liabilities, net		 0.94 3.80 -0.81 1.52 15 0.41 0.32 24 -28 34
Net Cash From Investing Activities		 -0.02 -0.10 -0.01 -0.03 -0.02 -0.05 -0.31 -54 -0.58 -0.27
Net Cash From Continuing Investing Activities		 -0.02 -0.10 -0.01 -0.03 -0.02 -0.05 -0.31 -54 -0.58 -0.27
Purchase of Property, Plant & Equipment		 -0.02 -0.10 -0.01 -0.03 -0.02 -0.05 -0.31 -0.70 -0.58 -0.27
Acquisitions		 - - - - - 0.00 0.00 -53 0.00 0.00
Net Cash From Financing Activities		 53 9.97 24 10 252 42 11 285 331 58
Net Cash From Continuing Financing Activities		 53 9.97 24 10 252 42 11 285 331 58
Repayment of Debt		 0.00 -0.06 -0.28 -3.36 -7.24 -23 -0.31 -0.49 -1.44 0.00
Repurchase of Common Equity		 - - - - 0.00 - -0.22 -6.98 -16 -0.82
Issuance of Debt		 7.44 10 0.00 0.00 20 50 0.00 45 85 0.00
Issuance of Common Equity		 46 0.00 24 13 238 14 7.44 250 259 71
Other Financing Activities, net		 0.00 0.03 0.48 0.51 1.39 1.05 4.23 -2.97 4.37 -13
Cash Interest Paid		 - 0.05 0.87 0.77 1.29 2.10 4.63 7.69 17 20

Quarterly Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 154 -27 46 191 -21 -30 -55 -16 12 -12 -14
Net Cash From Operating Activities		 -23 -28 -5.82 -55 -54 -30 -53 -30 -19 -26 -43
Net Cash From Continuing Operating Activities		 -23 -28 -5.82 -55 -54 -30 -53 -30 -19 -26 -43
Net Income / (Loss) Continuing Operations		 -45 -61 -11 -67 -62 -99 -68 -79 -65 -75 -59
Consolidated Net Income / (Loss)		 -45 -61 -11 -67 -62 -99 -68 -79 -65 -75 -59
Depreciation Expense		 0.07 0.09 0.09 0.10 0.14 0.13 0.13 0.14 0.13 0.13 0.15
Amortization Expense		 2.06 1.95 2.16 2.50 2.23 2.06 2.32 2.49 2.60 2.65 2.65
Non-Cash Adjustments To Reconcile Net Income		 8.67 15 13 23 15 63 19 24 38 33 23
Changes in Operating Assets and Liabilities, net		 11 17 -9.63 -14 -8.66 3.43 -6.81 23 5.08 13 -10
Net Cash From Investing Activities		 -0.07 -0.18 -0.07 -0.13 -0.37 -0.01 -0.10 -0.05 -0.09 -0.03 -0.34
Net Cash From Continuing Investing Activities		 -0.07 -0.18 -0.07 -0.13 -0.37 -0.01 -0.10 -0.05 -0.09 -0.03 -0.34
Purchase of Property, Plant & Equipment		 -0.07 -0.18 -0.07 -0.13 -0.37 -0.01 -0.10 -0.05 -0.09 -0.03 -0.34
Net Cash From Financing Activities		 177 1.07 52 246 33 -0.00 -1.19 14 30 14 29
Net Cash From Continuing Financing Activities		 177 1.07 52 246 33 -0.00 -1.19 14 30 14 29
Repurchase of Common Equity		 -5.22 - - - -2.05 - - - -0.26 -0.33 -0.39
Issuance of Common Equity		 180 6.25 - - 45 -11 - - 43 18 20
Other Financing Activities, net		 1.97 -5.19 -2.22 4.93 -8.75 10 -1.19 3.34 -12 -2.99 10
Cash Interest Paid		 2.53 2.57 3.22 3.92 4.73 4.87 4.90 5.01 5.02 4.76 4.59

Annual Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 49 38 36 15 221 186 88 331 588 568
Total Current Assets		 49 38 35 15 220 184 87 246 504 485
Cash & Equivalents		 48 37 34 14 220 184 86 201 386 315
Accounts Receivable		 - - - - - - 0.00 38 95 142
Inventories, net		 - - - - - - 0.00 4.32 15 16
Prepaid Expenses		 1.00 1.38 1.28 1.25 0.41 0.15 0.05 2.78 8.12 12
Plant, Property, & Equipment, net		 0.02 0.10 0.07 0.05 0.03 0.05 0.28 0.72 0.85 0.58
Total Noncurrent Assets		 0.03 0.11 0.19 0.11 0.14 2.06 0.98 85 83 83
Goodwill		 - - - - - - 0.00 10 12 12
Intangible Assets		 - - - - - - 0.00 60 53 47
Other Noncurrent Operating Assets		 0.03 0.11 0.19 0.11 0.14 2.06 0.98 15 18 24
Total Liabilities & Shareholders' Equity		 49 38 36 15 221 186 88 331 588 568
Total Liabilities		 2.63 17 19 14 42 72 72 222 397 511
Total Current Liabilities		 2.63 7.17 12 11 24 23 23 97 139 230
Short-Term Debt		 0.00 0.27 3.27 3.29 2.60 - 0.00 5.90 6.41 8.29
Accounts Payable		 2.63 6.90 6.11 7.53 22 22 22 90 131 220
Other Current Liabilities		 - 0.00 2.79 - 0.00 1.22 0.62 0.43 1.27 1.84
Total Noncurrent Liabilities		 0.00 9.47 6.66 3.62 17 49 49 125 258 281
Long-Term Debt		 0.00 9.47 6.66 3.62 17 48 49 94 178 181
Capital Lease Obligations		 - - - - - - - - 0.00 2.94
Other Noncurrent Operating Liabilities		 - - - - 0.00 0.58 0.00 31 80 98
Total Equity & Noncontrolling Interests		 46 22 17 0.94 179 114 16 110 191 57
Total Preferred & Common Equity		 46 22 17 0.94 179 114 16 110 191 57
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 46 22 17 0.94 179 114 16 110 191 57
Common Stock		 67 69 93 108 355 393 425 706 1,027 1,180
Retained Earnings		 -20 -48 -77 -108 -176 -279 -409 -596 -836 -1,123

Quarterly Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 339 389 612 601 546 548 561 597
Total Current Assets		 252 304 520 512 460 463 479 495
Cash & Equivalents		 228 247 437 417 331 316 327 301
Accounts Receivable		 20 45 67 78 101 120 124 161
Inventories, net		 2.10 7.94 9.25 9.99 16 15 14 16
Prepaid Expenses		 2.46 5.20 5.91 6.80 12 12 13 16
Plant, Property, & Equipment, net		 0.63 0.70 0.74 0.97 0.81 0.72 0.68 0.77
Total Noncurrent Assets		 86 84 91 88 84 84 82 101
Goodwill		 12 10 12 12 12 12 12 12
Intangible Assets		 61 58 57 55 52 50 49 45
Other Noncurrent Operating Assets		 13 16 23 21 21 22 21 44
Total Liabilities & Shareholders' Equity		 339 389 612 601 546 548 561 597
Total Liabilities		 182 277 333 331 402 445 469 543
Total Current Liabilities		 60 101 115 115 144 187 196 244
Short-Term Debt		 7.00 6.00 6.34 6.67 6.39 7.04 8.13 8.60
Accounts Payable		 53 95 108 108 137 178 186 235
Other Current Liabilities		 0.42 0.11 0.35 0.44 1.15 1.42 1.63 0.45
Total Noncurrent Liabilities		 121 177 218 217 258 259 272 300
Long-Term Debt		 94 148 177 177 179 179 180 181
Capital Lease Obligations		 - - - - 1.70 3.03 2.95 3.68
Other Noncurrent Operating Liabilities		 27 29 41 39 77 76 89 114
Total Equity & Noncontrolling Interests		 157 112 279 270 144 103 93 53
Total Preferred & Common Equity		 157 112 279 270 144 103 93 53
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 157 112 279 270 144 103 93 53
Common Stock		 692 719 954 1,006 1,048 1,086 1,141 1,235
Retained Earnings		 -535 -608 -675 -737 -904 -983 -1,048 -1,182

Annual Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 440.80% 42.53%
EBITDA Growth		 -12.35% -196.76% 0.57% -8.55% -124.62% -47.66% -25.72% -40.76% -27.89% -21.38%
EBIT Growth		 -62.41% -196.01% -0.97% -8.07% -123.74% -47.43% -25.79% -44.18% -28.94% -21.02%
NOPAT Growth		 -62.13% -199.51% 1.38% -20.92% -104.72% -47.43% -25.79% -44.18% -28.94% -21.02%
Net Income Growth		 -103.49% -122.77% -6.40% -6.99% -120.71% -50.56% -26.73% -43.50% -27.84% -20.05%
EPS Growth		 -54.55% -39.22% 10.56% 9.45% -74.78% -37.81% -25.27% -32.56% -14.57% -13.66%
Operating Cash Flow Growth		 -61.84% -186.08% -24.39% -13.53% -54.31% -69.18% -37.94% -7.66% -24.52% 11.49%
Free Cash Flow Firm Growth		 0.00% -221.23% -8.90% -43.03% -31.51% -116.25% -26.63% -79.24% 8.83% 1.36%
Invested Capital Growth		 0.00% -233.38% -38.89% 16.98% -248.18% -2.13% 0.04% 140.79% -221.03% -518.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 94.95% 21.11% 13.96%
EBITDA Q/Q Growth		 0.00% -18.57% 0.00% 0.00% -28.81% 15.47% -26.71% -17.24% -20.74% 8.86%
EBIT Q/Q Growth		 0.00% -18.89% 0.00% 0.00% -28.66% 15.23% -26.33% -17.91% -19.83% 8.38%
NOPAT Q/Q Growth		 0.00% -19.38% 0.00% 0.00% -28.66% 15.23% -26.33% -17.91% -19.83% 8.38%
Net Income Q/Q Growth		 0.00% -17.06% 0.00% 0.00% -28.63% 14.01% -24.83% -17.05% -18.54% 7.63%
EPS Q/Q Growth		 0.00% -10.94% 0.00% 0.00% -24.07% -2.59% -3.27% -13.30% -15.57% 9.24%
Operating Cash Flow Q/Q Growth		 0.00% -30.44% 3.38% -13.19% -20.14% -3.96% -8.29% 1.08% -1.97% 3.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 13.66% -33.41% 2.34% -0.66% -5.08%
Invested Capital Q/Q Growth		 0.00% 6.97% 0.00% 0.00% -24.89% -14.10% 4.30% -71.15% -128.98% -53.14%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 89.61% 90.37% 91.37%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -347.57% -82.19% -69.99%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -359.33% -85.67% -72.74%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -359.33% -85.67% -72.74%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -373.99% -88.41% -74.47%
Tax Burden Percent		 97.80% 98.29% 99.29% 99.30% 99.80% 99.95% 100.00% 100.00% 100.40% 100.03%
Interest Burden Percent		 134.18% 100.48% 104.82% 103.75% 101.84% 103.85% 104.57% 104.08% 102.78% 102.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -26.29% -79.99% -151.19% -350.78% -76.08% -70.36% -201.51% -298.97% -159.21% -231.63%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,763.61% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -85.77% -50.41% -48.51%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -89.27% -52.02% -49.66%
Return on Common Equity (ROCE)		 -26.29% -79.99% -151.19% -350.78% -76.08% -70.36% -201.51% -298.97% -159.21% -231.63%
Return on Equity Simple (ROE_SIMPLE)		 -26.29% -126.10% -173.14% -3,301.50% -38.24% -90.43% -834.29% -170.81% -125.27% -503.76%
Net Operating Profit after Tax (NOPAT)		 -6.44 -19 -19 -23 -47 -69 -87 -126 -162 -196
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -251.53% -59.97% -50.92%
Net Nonoperating Expense Percent (NNEP)		 -24.04% -21.15% -38.96% -51.20% -20.55% -19.97% -49.85% -88.76% -50.90% -55.87%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -60.01% -43.22% -78.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.39% 9.63% 8.63%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 318.27% 119.41% 106.65%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 115.81% 36.20% 48.50%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 448.94% 176.04% 164.11%
Earnings before Interest and Taxes (EBIT)		 -9.30 -28 -28 -30 -67 -99 -125 -180 -232 -281
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.25 -27 -27 -30 -67 -98 -124 -174 -222 -270
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.99 7.93 89.64 19.96 26.74 91.10 30.57 19.72 71.92
Price to Tangible Book Value (P/TBV)		 0.00 5.99 7.93 89.64 19.96 26.74 91.10 84.61 29.97 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 66.94 13.92 10.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 366.14 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 64.93 13.17 10.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.45 0.59 7.37 0.11 0.42 3.14 0.91 0.97 3.37
Long-Term Debt to Equity		 0.00 0.44 0.40 3.86 0.10 0.42 3.14 0.86 0.93 3.22
Financial Leverage		 -1.03 -1.10 -1.33 -1.76 -1.15 -1.15 -1.34 -1.10 -1.01 -1.31
Leverage Ratio		 1.06 1.28 1.93 2.89 1.31 1.39 2.12 3.35 3.06 4.66
Compound Leverage Factor		 1.42 1.29 2.02 2.99 1.34 1.44 2.21 3.49 3.15 4.77
Debt to Total Capital		 0.00% 31.11% 37.27% 88.05% 10.03% 29.81% 75.85% 47.76% 49.13% 77.10%
Short-Term Debt to Total Capital		 0.00% 0.86% 12.27% 41.94% 1.31% 0.00% 0.00% 2.81% 1.71% 3.33%
Long-Term Debt to Total Capital		 0.00% 30.25% 25.00% 46.11% 8.72% 29.81% 75.85% 44.95% 47.43% 73.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 68.89% 62.73% 11.95% 89.97% 70.19% 24.15% 52.24% 50.87% 22.90%
Debt to EBITDA		 0.00 -0.35 -0.36 -0.23 -0.30 -0.49 -0.40 -0.58 -0.83 -0.71
Net Debt to EBITDA		 0.00 0.98 0.88 0.24 3.01 1.38 0.30 0.58 0.91 0.46
Long-Term Debt to EBITDA		 0.00 -0.35 -0.24 -0.12 -0.26 -0.49 -0.40 -0.54 -0.80 -0.68
Debt to NOPAT		 0.00 -0.51 -0.52 -0.30 -0.42 -0.70 -0.56 -0.80 -1.14 -0.98
Net Debt to NOPAT		 0.00 1.39 1.27 0.31 4.25 1.95 0.43 0.80 1.24 0.63
Long-Term Debt to NOPAT		 0.00 -0.49 -0.35 -0.16 -0.37 -0.70 -0.56 -0.75 -1.10 -0.94
Altman Z-Score		 0.00 1.51 -0.59 -12.40 50.11 22.41 1.49 5.44 3.60 1.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 18.63 5.30 2.90 1.41 9.00 7.85 3.75 2.54 3.63 2.11
Quick Ratio		 18.25 5.11 2.79 1.29 8.98 7.85 3.75 2.47 3.46 1.99
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.85 -16 -17 -24 -32 -69 -87 -156 -143 -141
Operating Cash Flow to CapEx		 -36,835.81% -20,353.00% -267,444.45% -91,918.59% -287,668.62% -170,962.87% -35,138.31% -16,597.01% -24,927.84% -47,559.26%
Free Cash Flow to Firm to Interest Expense		 -1.98 0.00 0.00 0.00 0.00 -55.29 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -3.04 0.00 0.00 0.00 0.00 -62.92 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -3.05 0.00 0.00 0.00 0.00 -62.95 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.59 0.67
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.08 3.26
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.68 2.16
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 99.49 345.15 539.43
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.24 0.19
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 89.37 112.06
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 136.22 169.15
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,956.17 1,550.29 1,924.37
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,956.17 -1,324.70 -1,643.17
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -1.59 -5.31 -7.37 -6.12 -21 -22 -22 8.87 -11 -66
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.77 -290.03 -10.00
Increase / (Decrease) in Invested Capital		 -1.59 -3.72 -2.06 1.25 -15 -0.45 0.01 31 -20 -56
Enterprise Value (EV)		 0.00 102 108 77 3,367 2,907 1,387 3,249 3,564 3,977
Market Capitalization		 0.00 129 133 84 3,567 3,042 1,424 3,349 3,766 4,100
Book Value per Share		 $3.89 $1.13 $0.71 $0.03 $5.18 $3.06 $0.41 $2.52 $4.04 $1.18
Tangible Book Value per Share		 $3.89 $1.13 $0.71 $0.03 $5.18 $3.06 $0.41 $0.91 $2.66 ($0.04)
Total Capital		 46 31 27 7.85 199 162 65 210 375 249
Total Debt		 0.00 9.74 9.93 6.91 20 48 49 100 184 192
Total Long-Term Debt		 0.00 9.47 6.66 3.62 17 48 49 94 178 184
Net Debt		 -48 -27 -24 -7.06 -200 -136 -37 -101 -202 -123
Capital Expenditures (CapEx)		 0.02 0.10 0.01 0.03 0.02 0.05 0.31 0.70 0.58 0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.64 -5.52 -7.63 -6.28 -21 -23 -23 -46 -14 -52
Debt-free Net Working Capital (DFNWC)		 46 31 26 7.68 198 161 63 155 372 263
Net Working Capital (NWC)		 46 31 23 4.39 196 161 63 149 365 255
Net Nonoperating Expense (NNE)		 5.77 7.92 9.93 7.97 21 34 43 61 77 91
Net Nonoperating Obligations (NNO)		 -48 -27 -24 -7.06 -200 -136 -37 -101 -202 -123
Total Depreciation and Amortization (D&A)		 0.05 0.09 0.51 0.42 0.69 0.86 1.15 5.89 9.41 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -91.65% -5.31% -13.51%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 309.73% 137.40% 68.25%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 297.94% 135.04% 66.10%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.02) ($1.42) ($1.27) ($1.15) ($2.01) ($2.77) ($3.47) ($4.60) ($5.27) ($5.99)
Adjusted Weighted Average Basic Shares Outstanding		 11.95M 19.20M 25.49M 33.28M 37.08M 37.41M 38.48M 40.66M 45.43M 47.91M
Adjusted Diluted Earnings per Share		 ($1.02) ($1.42) ($1.27) ($1.15) ($2.01) ($2.77) ($3.47) ($4.60) ($5.27) ($5.99)
Adjusted Weighted Average Diluted Shares Outstanding		 11.95M 19.20M 25.49M 33.28M 37.08M 37.41M 38.48M 40.66M 45.43M 47.91M
Adjusted Basic & Diluted Earnings per Share		 ($1.02) ($1.42) ($1.27) ($1.15) ($2.01) ($2.77) ($3.47) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.95M 19.15M 22.76M 26.88M 34.02M 37.21M 37.62M 43.52M 47.37M 48.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.44 -19 -19 -23 -47 -69 -87 -126 -162 -196
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -251.53% -59.97% -50.92%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -373.99% -88.06% -74.45%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -3.81 0.00 0.00 0.00 0.00 -79.50 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -2.63 0.00 0.00 0.00 0.00 -55.65 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -3.81 0.00 0.00 0.00 0.00 -79.54 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2.64 0.00 0.00 0.00 0.00 -55.69 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.17% -3.73% -6.55% -0.28%

Quarterly Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 429.48% 243.07% 193.50% -20.70% 86.65% 81.27% 66.04% 61.95%
EBITDA Growth		 -19.63% -79.17% 89.07% -64.35% -48.34% -66.00% -1,470.37% -20.74% -0.24% 27.31% 16.42%
EBIT Growth		 -26.95% -83.75% 83.35% -66.04% -46.47% -64.02% -955.46% -19.97% -0.81% 26.11% 15.30%
NOPAT Growth		 -26.95% -83.75% 83.35% -66.04% -46.47% -64.02% -955.46% -19.97% -0.81% 26.11% 15.30%
Net Income Growth		 -28.50% -80.25% 71.69% -62.10% -38.77% -61.09% -509.35% -18.13% -3.86% 24.06% 13.08%
EPS Growth		 -15.05% -60.00% 74.76% -45.28% -23.36% -49.31% -453.85% -8.44% -1.52% 28.37% 15.28%
Operating Cash Flow Growth		 15.01% 4.43% 82.17% -65.04% -135.29% -10.15% -818.52% 45.60% 65.21% 13.70% 18.88%
Free Cash Flow Firm Growth		 -321.64% -217.80% -70.33% 67.41% 40.14% 32.23% 37.49% 78.17% 173.47% 109.82% 149.10%
Invested Capital Growth		 235.29% 140.79% 191.38% -39.70% 20.51% -221.03% -103.34% -194.19% -216.99% -518.31% -8,465.13%
Revenue Q/Q Growth		 91.00% 44.67% 288.07% -50.62% 23.76% 23.77% 4.85% 16.22% 20.19% 13.37% 2.27%
EBITDA Q/Q Growth		 -5.99% -43.70% 92.87% -1,413.06% 4.34% -60.80% 32.53% -16.33% 20.58% -16.61% 22.42%
EBIT Q/Q Growth		 -8.25% -41.27% 89.36% -920.66% 4.51% -58.20% 31.54% -16.01% 19.76% -15.96% 21.53%
NOPAT Q/Q Growth		 -8.25% -41.27% 89.36% -920.66% 4.51% -58.20% 31.54% -16.01% 19.76% -15.96% 21.53%
Net Income Q/Q Growth		 -8.17% -36.63% 81.68% -498.77% 7.40% -58.61% 30.71% -16.07% 18.58% -15.96% 20.69%
EPS Q/Q Growth		 -0.94% -34.58% 81.94% -492.31% 14.29% -62.88% 33.02% -15.97% 19.76% -14.93% 20.78%
Operating Cash Flow Q/Q Growth		 32.14% -21.11% 78.88% -850.85% 3.25% 43.30% -76.10% 43.68% 38.12% -40.64% -65.54%
Free Cash Flow Firm Q/Q Growth		 7.11% 12.75% 39.27% 33.79% -70.64% 1.23% 43.98% 76.88% 674.39% -86.80% 180.13%
Invested Capital Q/Q Growth		 -25.38% -71.15% 113.14% 31.41% 49.12% -128.98% 94.12% -3,609.98% -85.22% -53.14% 18.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.58% 90.60% 92.01% 90.15% 88.70% 89.69% 91.60% 90.76% 91.95% 91.15% 91.94%
EBITDA Margin		 -239.10% -237.49% -4.36% -133.75% -103.38% -134.32% -86.43% -86.52% -57.17% -58.80% -44.61%
Operating Margin		 -251.76% -245.85% -6.74% -139.31% -107.49% -137.39% -89.70% -89.54% -59.78% -61.14% -46.91%
EBIT Margin		 -251.76% -245.85% -6.74% -139.31% -107.49% -137.39% -89.70% -89.54% -59.78% -61.14% -46.91%
Profit (Net Income) Margin		 -266.08% -251.29% -11.86% -143.83% -107.62% -137.92% -91.14% -91.03% -61.67% -63.08% -48.91%
Tax Burden Percent		 100.00% 100.00% 129.87% 99.09% 98.92% 99.67% 100.00% 100.00% 100.00% 100.11% 100.00%
Interest Burden Percent		 105.68% 102.21% 135.52% 104.20% 101.22% 100.71% 101.61% 101.66% 103.16% 103.04% 104.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,127.57% 0.00% 0.00% -538.73% -495.80% 0.00% -1,724.41% -25,321.38% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,111.81% 0.00% 0.00% -519.75% -485.37% 0.00% -1,706.51% -25,308.38% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1,067.23% 0.00% 0.00% 402.95% 408.26% 0.00% 1,584.57% 25,212.69% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -60.34% -298.97% -250.92% -135.77% -87.54% -159.21% -139.84% -108.69% -171.61% -231.63% -282.16%
Cash Return on Invested Capital (CROIC)		 -521.00% -1,763.61% -756.81% -318.68% -418.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -28.37% -58.68% -4.08% -64.18% -51.11% -80.85% -48.17% -45.00% -34.81% -40.77% -35.49%
Return on Assets (ROA)		 -29.98% -59.98% -7.18% -66.27% -51.17% -81.16% -48.94% -45.75% -35.91% -42.06% -37.01%
Return on Common Equity (ROCE)		 -60.34% -298.97% -250.92% -135.77% -87.54% -159.21% -139.84% -108.69% -171.61% -231.63% -282.16%
Return on Equity Simple (ROE_SIMPLE)		 -101.59% 0.00% -141.95% -66.16% -74.89% 0.00% -205.77% -300.00% -334.73% 0.00% -523.02%
Net Operating Profit after Tax (NOPAT)		 -30 -42 -4.46 -46 -43 -69 -47 -55 -44 -51 -40
NOPAT Margin		 -176.23% -172.10% -4.72% -97.52% -75.24% -96.17% -62.79% -62.68% -41.84% -42.80% -32.84%
Net Nonoperating Expense Percent (NNEP)		 -15.76% -27.96% -10.53% -18.98% -10.42% -19.75% -17.90% -13.00% -11.26% -14.81% -15.50%
Return On Investment Capital (ROIC_SIMPLE)		 - -20.00% - - - -18.32% - - - -20.42% -16.16%
Cost of Revenue to Revenue		 11.42% 9.40% 7.99% 9.85% 11.30% 10.31% 8.40% 9.24% 8.05% 8.85% 8.06%
SG&A Expenses to Revenue		 242.74% 252.34% 78.45% 169.03% 143.94% 121.36% 131.96% 118.80% 91.22% 95.37% 99.44%
R&D to Revenue		 88.31% 60.29% 18.81% 44.07% 49.78% 43.06% 49.11% 57.19% 43.32% 46.31% 36.87%
Operating Expenses to Revenue		 340.34% 336.45% 98.75% 229.46% 196.18% 227.07% 181.31% 180.30% 151.72% 152.29% 138.85%
Earnings before Interest and Taxes (EBIT)		 -42 -60 -6.37 -65 -62 -98 -67 -78 -63 -73 -57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -58 -4.13 -62 -60 -96 -65 -75 -60 -70 -54
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 11.43 30.57 24.01 11.23 12.24 19.72 26.22 37.17 46.44 71.92 106.90
Price to Tangible Book Value (P/TBV)		 21.36 84.61 61.83 14.89 16.28 29.97 47.03 93.93 133.33 0.00 0.00
Price to Revenue (P/Rev)		 70.07 66.94 18.56 17.16 14.76 13.92 15.04 13.12 12.75 10.63 13.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 54.36 366.14 137.01 115.77 82.72 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 65.14 64.93 17.92 15.77 13.72 13.17 14.47 12.68 12.34 10.31 12.91
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.64 0.91 1.37 0.66 0.68 0.97 1.30 1.84 2.06 3.37 3.64
Long-Term Debt to Equity		 0.60 0.86 1.32 0.63 0.66 0.93 1.25 1.77 1.97 3.22 3.48
Financial Leverage		 -0.96 -1.10 -1.01 -0.78 -0.84 -1.01 -0.93 -1.00 -1.02 -1.31 -1.28
Leverage Ratio		 2.28 3.35 3.78 2.69 2.20 3.06 3.65 3.04 3.21 4.66 5.79
Compound Leverage Factor		 2.41 3.42 5.12 2.81 2.23 3.08 3.71 3.09 3.31 4.81 6.04
Debt to Total Capital		 39.07% 47.76% 57.87% 39.65% 40.59% 49.13% 56.46% 64.81% 67.29% 77.10% 78.45%
Short-Term Debt to Total Capital		 2.71% 2.81% 2.26% 1.37% 1.47% 1.71% 1.93% 2.41% 2.86% 3.33% 3.48%
Long-Term Debt to Total Capital		 36.36% 44.95% 55.61% 38.28% 39.12% 47.43% 54.53% 62.40% 64.42% 73.77% 74.96%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 60.93% 52.24% 42.13% 60.35% 59.41% 50.87% 43.54% 35.19% 32.71% 22.90% 21.55%
Debt to EBITDA		 -0.68 -0.58 -1.10 -1.11 -1.00 -0.83 -0.66 -0.64 -0.65 -0.71 -0.75
Net Debt to EBITDA		 0.85 0.58 0.66 1.54 1.26 0.91 0.51 0.43 0.46 0.46 0.41
Long-Term Debt to EBITDA		 -0.63 -0.54 -1.05 -1.07 -0.96 -0.80 -0.64 -0.62 -0.62 -0.68 -0.71
Debt to NOPAT		 -0.95 -0.80 -1.48 -1.51 -1.36 -1.14 -0.91 -0.89 -0.89 -0.98 -1.02
Net Debt to NOPAT		 1.19 0.80 0.90 2.09 1.72 1.24 0.71 0.59 0.64 0.63 0.57
Long-Term Debt to NOPAT		 -0.88 -0.75 -1.43 -1.45 -1.31 -1.10 -0.88 -0.85 -0.85 -0.94 -0.98
Altman Z-Score		 4.07 6.63 4.57 4.84 5.08 4.35 4.07 3.31 3.75 2.84 4.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.19 2.54 3.02 4.52 4.46 3.63 3.20 2.48 2.44 2.11 2.03
Quick Ratio		 4.11 2.47 2.89 4.39 4.32 3.46 3.01 2.34 2.30 1.99 1.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -83 -73 -44 -29 -50 -49 -28 -6.37 37 4.83 14
Operating Cash Flow to CapEx		 -34,481.82% -15,228.18% -8,198.59% -41,615.79% -14,433.42% -433,742.86% -54,558.16% -57,903.85% -20,701.11% -87,340.00% -12,832.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.11 0.24 0.61 0.46 0.48 0.59 0.54 0.50 0.58 0.67 0.76
Accounts Receivable Turnover		 0.00 0.00 0.00 4.37 4.53 4.08 3.43 3.11 3.34 3.26 3.29
Inventory Turnover		 0.00 0.00 0.00 1.67 3.47 2.68 2.11 2.31 2.49 2.16 2.31
Fixed Asset Turnover		 54.50 99.49 248.49 266.29 279.65 345.15 331.38 399.30 409.26 539.43 545.31
Accounts Payable Turnover		 0.08 0.09 0.22 0.23 0.26 0.24 0.21 0.20 0.21 0.19 0.20
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 83.58 80.63 89.37 106.31 117.55 109.20 112.06 110.99
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 218.24 105.16 136.22 173.06 158.03 146.70 169.15 158.23
Days Payable Outstanding (DPO)		 4,814.76 3,956.17 1,690.30 1,607.53 1,395.57 1,550.29 1,699.86 1,849.36 1,778.48 1,924.37 1,841.94
Cash Conversion Cycle (CCC)		 -4,814.76 -3,956.17 -1,690.30 -1,305.71 -1,209.78 -1,324.70 -1,420.49 -1,573.79 -1,522.58 -1,643.17 -1,572.71
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 31 8.87 19 25 37 -11 -0.63 -23 -43 -66 -54
Invested Capital Turnover		 6.40 -7.77 -162.02 5.52 6.59 -290.03 27.46 404.00 -107.50 -10.00 -15.81
Increase / (Decrease) in Invested Capital		 53 31 40 -16 6.31 -20 -20 -48 -80 -56 -53
Enterprise Value (EV)		 1,672 3,249 2,591 2,877 3,066 3,564 3,631 3,697 4,178 3,977 5,580
Market Capitalization		 1,798 3,349 2,684 3,131 3,298 3,766 3,776 3,823 4,314 4,100 5,688
Book Value per Share		 $3.90 $2.52 $2.57 $6.40 $5.71 $4.04 $3.04 $2.17 $1.94 $1.18 $1.09
Tangible Book Value per Share		 $2.09 $0.91 $1.00 $4.83 $4.29 $2.66 $1.69 $0.86 $0.67 ($0.04) ($0.09)
Total Capital		 258 210 265 462 454 375 331 292 284 249 247
Total Debt		 101 100 154 183 184 184 187 189 191 192 194
Total Long-Term Debt		 94 94 148 177 177 178 180 182 183 184 185
Net Debt		 -127 -101 -93 -254 -232 -202 -145 -126 -136 -123 -107
Capital Expenditures (CapEx)		 0.07 0.18 0.07 0.13 0.37 0.01 0.10 0.05 0.09 0.03 0.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -46 -37 -26 -13 -14 -8.61 -32 -36 -52 -42
Debt-free Net Working Capital (DFNWC)		 199 155 210 411 404 372 323 283 291 263 259
Net Working Capital (NWC)		 192 149 204 405 397 365 316 276 283 255 251
Net Nonoperating Expense (NNE)		 15 19 6.76 22 19 30 21 25 21 24 20
Net Nonoperating Obligations (NNO)		 -127 -101 -93 -254 -232 -202 -145 -126 -136 -123 -107
Total Depreciation and Amortization (D&A)		 2.13 2.04 2.25 2.60 2.37 2.19 2.45 2.63 2.73 2.78 2.80
Debt-free, Cash-free Net Working Capital to Revenue		 -110.73% -91.65% -25.39% -14.28% -5.72% -5.31% -3.43% -11.03% -10.72% -13.51% -9.62%
Debt-free Net Working Capital to Revenue		 775.74% 309.73% 145.07% 225.24% 180.71% 137.40% 128.61% 97.26% 86.00% 68.25% 60.01%
Net Working Capital to Revenue		 748.46% 297.94% 140.93% 221.77% 177.72% 135.04% 126.06% 94.84% 83.59% 66.10% 58.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.07) ($1.44) ($0.26) ($1.54) ($1.32) ($2.15) ($1.44) ($1.67) ($1.34) ($1.54) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 41.70M 40.66M 43.52M 43.67M 47.12M 45.43M 47.39M 47.57M 48.14M 47.91M 48.87M
Adjusted Diluted Earnings per Share		 ($1.07) ($1.44) ($0.26) ($1.54) ($1.32) ($2.15) ($1.44) ($1.67) ($1.34) ($1.54) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 41.70M 40.66M 43.52M 43.67M 47.12M 45.43M 47.39M 47.57M 48.14M 47.91M 48.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.43M 43.52M 43.57M 47.19M 47.32M 47.37M 47.50M 48.00M 48.46M 48.77M 49.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -42 -4.46 -46 -43 -69 -47 -55 -44 -51 -40
Normalized NOPAT Margin		 -176.23% -172.10% -4.72% -97.52% -75.24% -96.17% -62.79% -62.68% -41.84% -42.80% -32.84%
Pre Tax Income Margin		 -266.08% -251.29% -9.13% -145.15% -108.80% -138.37% -91.14% -91.03% -61.67% -63.00% -48.91%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.73% 0.00% -10.21% -7.76% -6.55% 0.00% -0.74% -0.16% -0.28% -0.43%

Key Financial Trends

Axsome Therapeutics (NASDAQ: AXSM) continues to reflect a challenging operational environment through the most recent quarter (Q1 2025) and has shown a consistent pattern over the last several years. Below are the key financial trends and observations based on the income statements, cash flow statements, and balance sheets from Q3 2022 through Q1 2025.

  • Revenue Growth: Operating revenue increased steadily over the last quarters from $16.8 million in Q3 2022 to $121.5 million in Q1 2025, showing strong top-line growth.
  • Improving Gross Profit: Total gross profit has increased consistently, reaching $111.7 million in Q1 2025 up from $14.9 million in Q3 2022, reflecting improved operational scale.
  • Strong Cash Position: Cash and equivalents rose from approximately $227.5 million in Q3 2022 to over $300.9 million in Q1 2025, providing liquidity for growth and R&D.
  • Equity Increase: Total common equity remains positive at $53.2 million in Q1 2025, though it fluctuated over time, indicating some strengthening of the equity base after previous losses.
  • Capital Raising: The company raised significant funds through issuance of common equity in multiple quarters, supporting financial flexibility (e.g., $19.7 million raised in Q1 2025).
  • Research & Development (R&D) Expense: R&D costs have generally increased, aligning with a growth strategy in product development but also pressuring earnings (Q1 2025: $44.8 million).
  • Selling, General & Administrative (SG&A) Expense: Remains elevated, over $100 million in recent quarters, which may reflect ongoing commercial investment and operational costs.
  • Total Operating Expenses: Increase in line with revenue growth; Q1 2025 reported $168.7 million in operating expenses, up from $57.3 million in Q3 2022.
  • Negative Operating Income: Despite revenue growth, operating income remains negative across all quarters, though with some improvement from -$98.3 million in Q4 2023 to -$56.9 million in Q1 2025.
  • Consistent Net Losses: The company continues to report net losses every quarter, ranging from approximately -$44.8 million in Q3 2022 to -$59.4 million in Q1 2025, indicating ongoing unprofitability.
  • High and Rising Operating Expenses: The steep increase in operating expenses, particularly SG&A and R&D, is a significant drag on profitability.
  • Negative Cash Flow from Operations: Operating cash flow has been negative consistently, e.g., -$43.4 million in Q1 2025, suggesting cash burn from core activities.
  • Increased Liabilities: Total liabilities have grown from $181.6 million in Q3 2022 to $543.5 million in Q1 2025, driven notably by higher long-term debt ($181.4 million in Q1 2025), adding financial risk.
  • Declining Equity Base Until Recent Quarter: Retained earnings have been deeply negative, reflecting accumulated losses, with equity shrinking from $157.4 million in Q3 2022 to around $53 million in Q1 2025.

Summary: Axsome Therapeutics shows robust revenue growth and improving gross profit, indicative of market adoption and operational scale. However, the company remains unprofitable with large operating losses and negative operating cash flows driven mainly by high SG&A and R&D expenses. The increasing debt load and historical equity erosion underline the financial risks involved. Investors should monitor Axsome's path toward profitability and how it manages expense control and debt.

08/25/25 02:59 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Axsome Therapeutics' Financials

When does Axsome Therapeutics' financial year end?

According to the most recent income statement we have on file, Axsome Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Axsome Therapeutics' net income changed over the last 9 years?

Axsome Therapeutics' net income appears to be on an upward trend, with a most recent value of -$287.22 million in 2024, rising from -$12.21 million in 2015. The previous period was -$239.24 million in 2023. Find out what analysts predict for Axsome Therapeutics in the coming months.

What is Axsome Therapeutics' operating income?
Axsome Therapeutics' total operating income in 2024 was -$280.56 million, based on the following breakdown:
  • Total Gross Profit: $352.39 million
  • Total Operating Expenses: $632.95 million
How has Axsome Therapeutics' revenue changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' total revenue changed from $0.00 in 2015 to $385.69 million in 2024, a change of 38,569,300,000.0%.

How much debt does Axsome Therapeutics have?

Axsome Therapeutics' total liabilities were at $511.48 million at the end of 2024, a 28.8% increase from 2023, and a 19,334.0% increase since 2015.

How much cash does Axsome Therapeutics have?

In the past 9 years, Axsome Therapeutics' cash and equivalents has ranged from $13.97 million in 2018 to $386.19 million in 2023, and is currently $315.35 million as of their latest financial filing in 2024.

How has Axsome Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' book value per share changed from 3.89 in 2015 to 1.18 in 2024, a change of -69.7%.


Related Companies

This page (NASDAQ:AXSM) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...
Weiss Ratings | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel